<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00168818</url>
  </required_header>
  <id_info>
    <org_study_id>1160.48</org_study_id>
    <secondary_id>2004-001988-21</secondary_id>
    <nct_id>NCT00168818</nct_id>
  </id_info>
  <brief_title>Dabigatran Etexilate in Extended Venous Thromboembolism (VTE) Prevention After Hip Replacement Surgery</brief_title>
  <official_title>A Phase III Randomised, Parallel Group, Double-blind, Active Controlled Study to Investigate the Efficacy and Safety of Two Different Dose Regimens of Orally Administered Dabigatran Etexilate Capsules [150 or 220 mg Once Daily Starting With Half Dose (75 or 110 mg) on the Day of Surgery] Compared to Subcutaneous Enoxaparin 40 mg Once Daily for 28-35 Days, in Prevention of Venous Thromboembolism in Patients With Primary Elective Total Hip Replacement Surgery. RE-NOVATE (Extended Thromboembolism Prevention After Hip Surgery)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The objective of this study is to determine the comparative efficacy and safety of two oral
      regimens of dabigatran etexilate, compared to a standard subcutaneous regimen of enoxaparin,
      in prevention of venous thromboembolism in patients with primary elective total hip
      replacement surgery.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2004</start_date>
  <primary_completion_date type="Actual">July 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Venous Thromboembolic Event and All-cause Mortality During Treatment Period</measure>
    <time_frame>First administration until 31-38 days</time_frame>
    <description>Total Venous Thromboembolic Event (VTE) includes both proximal and distal deep vein thrombosis (DVT) (detected by routine bilateral venography), symptomatic DVT (confirmed by venous compression ultrasound, venography or autopsy) and pulmonary embolism (PE) (confirmed by pulmonary V-Q scintigraphy, chest x-ray, pulmonary angiography, spiral CT or autopsy).
All of these components and all deaths were centrally adjudicated by the VTE events committee, which was not aware of the treatment allocation of the patients.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major Venous Thromboembolic Event and Venous Thromboembolic Event-related Mortality During Treatment Period</measure>
    <time_frame>First administration until 31-38 days</time_frame>
    <description>Major Venous Thromboembolic Event (VTE) is defined as proximal DVT and PE, as adjudicated by the VTE events committee</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proximal Deep Vein Thrombosis During Treatment Period</measure>
    <time_frame>First administration until 31-38 days</time_frame>
    <description>Proximal Deep Vein Thrombosis as adjudicated by the VTE events committee</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Deep Vein Thrombosis During Treatment Period</measure>
    <time_frame>First administration until 31-38 days</time_frame>
    <description>Total Deep Vein Thrombosis as adjudicated by the VTE events committee</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptomatic Deep Vein Thrombosis During Treatment Period</measure>
    <time_frame>First administration until 31-38 days</time_frame>
    <description>Symptomatic Deep Vein Thrombosis, confirmed by venous compression ultrasound, venography or autopsy, and as adjudicated by the VTE events committee</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary Embolism During Treatment Period</measure>
    <time_frame>First administration until 31-38 days</time_frame>
    <description>Pulmonary embolism confirmed by pulmonary V-Q scintigraphy, chest x-ray, pulmonary angiography, spiral CT or autopsy, and as adjudicated by the VTE events committee</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death During Treatment Period</measure>
    <time_frame>First administration until 31-38 days</time_frame>
    <description>All cause death, as adjudicated by the VTE events committee</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Venous Thromboembolic Event (VTE) and All-cause Mortality During the Follow-up Period</measure>
    <time_frame>end of treatment to day 91±7</time_frame>
    <description>Total Venous Thromboembolic Event (VTE) includes both proximal and distal deep vein thrombosis (DVT) (detected by routine bilateral venography), symptomatic DVT (confirmed by venous compression ultrasound, venography or autopsy) and pulmonary embolism (PE) (confirmed by pulmonary V-Q scintigraphy, chest x-ray, pulmonary angiography, spiral CT or autopsy).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Bleeding Events (Defined According to Modified McMaster Criteria) During Treatment Period</measure>
    <time_frame>First administration until 31-38 days</time_frame>
    <description>Major bleeding events were defined as
fatal
clinically overt associated with loss of haemoglobin &gt;=20g/L in excess of what was expected
clinically overt leading to the transfusion of &gt;=2 units packed cells or whole blood in excess of what was expected
symptomatic retroperitoneal, intracranial, intraocular or intraspinal
requiring treatment cessation
leading to re-operation
Clinically-relevant was defined as
spontaneous skin hematoma greater than or equal to 25 cm²
wound hematoma greater than or equal to 100 cm²
spontaneous nose bleed lasting longer than 5 min
macroscopic hematuria spontaneous or lasting longer than 24 hours if associated with an intervention
spontaneous rectal bleeding (more than a spot on toilet paper)
gingival bleeding lasting longer than 5 min
any other bleeding event considered clinically relevant by the investigator
Minor bleeding events were defined as all other bleeding events that did not fulfil the criteria from above.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Transfusion</measure>
    <time_frame>Day 1</time_frame>
    <description>Blood transfusion for treated and operated patients on Day of surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of Blood Loss</measure>
    <time_frame>Day 1</time_frame>
    <description>Volume of blood loss for treated and operated patients during surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Analyses</measure>
    <time_frame>First administration to end of study</time_frame>
    <description>Frequency of patients with possible clinically significant abnormalities.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">3494</enrollment>
  <condition>Thromboembolism</condition>
  <condition>Arthroplasty, Replacement, Hip</condition>
  <arm_group>
    <arm_group_label>dabigatran etexilate 75 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>daily dose 150 mg once daily, half a dose on the day of surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dabigatran etexilate 110 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>daily dose 220 mg once daily, half a dose on the day of surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>enoxaparin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>40 mg once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dabigatran etexilate</intervention_name>
    <description>daily dose 150 mg once daily, half a dose on the day of surgery</description>
    <arm_group_label>dabigatran etexilate 75 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dabigatran etexilate</intervention_name>
    <description>daily dose 150 mg once daily, half a dose on the day of surgery</description>
    <arm_group_label>dabigatran etexilate 110 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>enoxaparin</intervention_name>
    <description>40 mg once daily</description>
    <arm_group_label>enoxaparin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

        Inclusion criteria (selected):

          -  Patients (18 years or older) scheduled to undergo a primary, unilateral, elective
             total hip replacement

          -  Written Informed Consent

        Exclusion criteria

        Exclusion criteria (selected):

          -  Patients with an excessive risk of bleeding, for example because of history of
             bleeding diathesis major surgery or trauma within the last 3 months history of
             haemorrhagic stroke or any of the following intracranial pathologies: bleeding,
             neoplasm, AV malformation or aneurysm clinically relevant bleeding or gastric /
             duodenal ulcer within the last 6 months treatment with anticoagulants within 7 days
             prior to joint replacement surgery or anticipated need during the study treatment
             period thrombocytopenia.

          -  Active malignant disease or current cytostatic treatment

          -  Known severe renal insufficiency

          -  Liver disease expected to have any potential impact on survival, or elevated AST or
             ALT &gt; 2x upper limit of normal

          -  Recent unstable cardiovascular disease or history of myocardial infarction within the
             last 3 months

          -  Pre-menopausal women who are pregnant or nursing, or are of child-bearing potential
             and are not practising or do not plan to continue practising acceptable methods of
             birth control

          -  Allergy to radio opaque contrast media or iodine, heparins (incl. heparin induced
             thrombocytopenia) or dabigatran

          -  Contraindications to enoxaparin

          -  Participation in a clinical trial during the last 30 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1160.48.06108 Canberra Hospital</name>
      <address>
        <city>Garren</city>
        <state>Australian Capital Territory</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.48.06106 St George Public Hospital</name>
      <address>
        <city>Kogarah</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.48.06110 Suite 13 level 4</name>
      <address>
        <city>Lismore</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.48.06105 Flinders Medical Centre</name>
      <address>
        <city>Bedford Park</city>
        <state>South Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.48.06104 Ecru</name>
      <address>
        <city>Box Hill</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.48.06102 Monash Medical Centre</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.48.06101 Emeritus Research</name>
      <address>
        <city>Malvern</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.48.06103 Maroondah Hospital</name>
      <address>
        <city>Ringwood East</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.48.06113</name>
      <address>
        <city>Windsor</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.48.06111 Haemophillia &amp; Thrombosis Service</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.48.04304 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Linz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.48.04303 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wels</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.48.04302 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.48.04301 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wr. Neustadt</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.48.03207 UVC Brugmann</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.48.03206 Campus Sint-Lucas</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.48.03208 UZ Gent</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.48.03202 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hasselt</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.48.03203 AZ Sint Elisabeth</name>
      <address>
        <city>Herentals</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.48.03205 Ziekenhuis Oost-Limburg</name>
      <address>
        <city>Lanaken</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.48.03201 UZ Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.48.42004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Brno-Bohunice</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.48.42010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chomutov</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.48.42009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Havlickuv Brod</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.48.42008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Jihlava</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.48.42002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kladno</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.48.42006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kolin</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.48.42003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ostrava</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.48.42001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Plzen</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.48.42007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pradubice</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.48.42005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Prague 8</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.48.04571 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hellerup</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.48.04570 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hørsholm</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.48.04573 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>København NV</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.48.04574 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>København S</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.48.04575 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Silkeborg</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.48.35803 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.48.35802 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Jyväskylä</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.48.35801 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oulu</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.48.35804 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seinäjoki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.48.35805 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tampere</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.48.03304 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Amiens cedex 1</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.48.03303 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Roubaix cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.48.03302 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Soyaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.48.03308 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.48.04906 Caritaskrankenhaus</name>
      <address>
        <city>Bad Mergentheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.48.04910 F.-A.-Universität Erlangen-Nürnberg</name>
      <address>
        <city>Erlangen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.48.04904 Orthopädische Universitätsklinik</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.48.04902 Klinikum Garmisch-Partenkirchen</name>
      <address>
        <city>Garmisch-Partenkirchen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.48.04914 St. Bernhard-Hospital</name>
      <address>
        <city>Kamp-Lintfort</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.48.04907 Johannes Gutenberg-Universität Mainz</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.48.04912 Orthopädische Klinik Markgröningen gGmbH</name>
      <address>
        <city>Markgröningen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.48.04901 Kreiskrankenhaus</name>
      <address>
        <city>Rheinfelden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.48.04915 Orthopädische Klinik Lindenlohe</name>
      <address>
        <city>Schwandorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.48.04903 Hellmuth-Ulrici-Kliniken</name>
      <address>
        <city>Sommerfeld</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.48.04905 Aukammklinik</name>
      <address>
        <city>Wiesbaden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.48.03603 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.48.03606 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.48.03607 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Békéscsaba</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.48.03601 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gyula</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.48.03604 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kecskemét</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.48.03602 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Szeged</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.48.03605 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Székesfehérvár</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.48.03903 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bergamo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.48.03904 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.48.03902 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.48.03901 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.48.03102 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.48.03101 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Heemstede</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.48.03107 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Helmond</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.48.03103 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hilversum</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.48.03104 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.48.03105 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sittard</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.48.04701 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bodø</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.48.04704 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bærum Postterminal</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.48.04707 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bærum Postterminal</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.48.04706 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Elverum</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.48.04702 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Skien</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.48.04703 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ålesund</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.48.04810 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bialystok</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.48.04804 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kielce</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.48.04806 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.48.04807 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.48.04812 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.48.04820 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lodz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.48.04814 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mielec</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.48.04808 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Piekary Slaskie</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.48.04817 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rzeszow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.48.04801 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.48.04802 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.48.04803 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.48.02701 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bryanston</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.48.02704 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Johannesburg</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.48.02703 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Randburg</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.48.02702 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sandton</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.48.03405 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Alcorcón (Madrid)</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.48.03403 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.48.03411 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.48.03407 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hospitalet (Barcelona)</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.48.03409 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Jaén</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.48.03401 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.48.03402 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.48.03404 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.48.03406 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.48.03408 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Móstoles (Madrid)</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.48.03410 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.48.04602 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Falköping</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.48.04601 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Göteborg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.48.04607 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Halmstad</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.48.04606 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kalmar</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.48.04603 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kungälv</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.48.04608 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lidköping</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.48.04605 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Linköping</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.48.04604 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mölndal</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.48.04610 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.48.04609 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Varberg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Czech Republic</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2005</study_first_posted>
  <results_first_submitted>November 18, 2010</results_first_submitted>
  <results_first_submitted_qc>November 18, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 20, 2010</results_first_posted>
  <last_update_submitted>May 8, 2014</last_update_submitted>
  <last_update_submitted_qc>May 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 19, 2014</last_update_posted>
  <responsible_party>
    <name_title>Boehringer Ingelheim, Study Chair</name_title>
    <organization>Boehringer Ingelheim</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dabigatran</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The treatment period is from first administration of study medication, until 3 days after last administration of study medication. Treatment duration is planned for 28 - 35 days. The study period is from first administration of study medication until day 84 - 91.</recruitment_details>
      <pre_assignment_details>Whilst 3494 patients were enrolled/randomised to treatment prior to surgery in this trial, only 3463 started treatment. Therefore, 31 patients were randomised but not treated (treatment was planned to start post surgery).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Dabigatran 220mg</title>
          <description>Patients were treated with 220mg dabigatran etexilate once daily as capsules for oral administration and placebo subcutaneous injections. Placebo injections matching the enoxaparin syringes.</description>
        </group>
        <group group_id="P2">
          <title>Dabigatran 150mg</title>
          <description>Patients were treated with 150mg dabigatran etexilate once daily as capsules for oral administration and placebo subcutaneous injections. Placebo injections matching the enoxaparin syringes.</description>
        </group>
        <group group_id="P3">
          <title>Enoxaparin</title>
          <description>Patients were treated with 40mg Enoxaparin once daily for subcutaneous injection and placebo capsules. Placebo capsules matching the dabigatran capsules.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1146"/>
                <participants group_id="P2" count="1163"/>
                <participants group_id="P3" count="1154"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1029"/>
                <participants group_id="P2" count="1054"/>
                <participants group_id="P3" count="1030"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="117"/>
                <participants group_id="P2" count="109"/>
                <participants group_id="P3" count="124"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="29"/>
                <participants group_id="P3" count="31"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="41"/>
                <participants group_id="P3" count="37"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>not specified</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="30"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Treatment</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1146"/>
                <participants group_id="P2" count="1163"/>
                <participants group_id="P3" count="1154"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1013"/>
                <participants group_id="P2" count="1012"/>
                <participants group_id="P3" count="1021"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="133"/>
                <participants group_id="P2" count="151"/>
                <participants group_id="P3" count="133"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="77"/>
                <participants group_id="P2" count="89"/>
                <participants group_id="P3" count="68"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="22"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>not specified</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="29"/>
                <participants group_id="P3" count="31"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Dabigatran 220mg</title>
          <description>Patients were treated with 220mg dabigatran etexilate once daily as capsules for oral administration and placebo subcutaneous injections. Placebo injections matching the enoxaparin syringes.</description>
        </group>
        <group group_id="B2">
          <title>Dabigatran 150mg</title>
          <description>Patients were treated with 150mg dabigatran etexilate once daily as capsules for oral administration and placebo subcutaneous injections. Placebo injections matching the enoxaparin syringes.</description>
        </group>
        <group group_id="B3">
          <title>Enoxaparin</title>
          <description>Patients were treated with 40mg Enoxaparin once daily for subcutaneous injection and placebo capsules. Placebo capsules matching the dabigatran capsules.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1146"/>
            <count group_id="B2" value="1163"/>
            <count group_id="B3" value="1154"/>
            <count group_id="B4" value="3463"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.6" spread="10.4"/>
                    <measurement group_id="B2" value="63.4" spread="11.1"/>
                    <measurement group_id="B3" value="63.8" spread="10.8"/>
                    <measurement group_id="B4" value="63.9" spread="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="636"/>
                    <measurement group_id="B2" value="667"/>
                    <measurement group_id="B3" value="651"/>
                    <measurement group_id="B4" value="1954"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="510"/>
                    <measurement group_id="B2" value="496"/>
                    <measurement group_id="B3" value="503"/>
                    <measurement group_id="B4" value="1509"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index N=(1146;1163;1151;3460)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.7" spread="4.6"/>
                    <measurement group_id="B2" value="27.8" spread="4.6"/>
                    <measurement group_id="B3" value="27.5" spread="4.3"/>
                    <measurement group_id="B4" value="27.7" spread="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Total Venous Thromboembolic Event and All-cause Mortality During Treatment Period</title>
        <description>Total Venous Thromboembolic Event (VTE) includes both proximal and distal deep vein thrombosis (DVT) (detected by routine bilateral venography), symptomatic DVT (confirmed by venous compression ultrasound, venography or autopsy) and pulmonary embolism (PE) (confirmed by pulmonary V-Q scintigraphy, chest x-ray, pulmonary angiography, spiral CT or autopsy).
All of these components and all deaths were centrally adjudicated by the VTE events committee, which was not aware of the treatment allocation of the patients.</description>
        <time_frame>First administration until 31-38 days</time_frame>
        <population>Full Analysis Set (all patients who had surgery and were randomised, received treatment, had an evaluable venogram for distal and proximal Deep Vein Thrombosis, or symptomatic Deep Vein Thrombosis, Pulmonary Embolism, or had died)</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran 220mg</title>
            <description>Patients were treated with 220mg dabigatran etexilate once daily as capsules for oral administration and placebo subcutaneous injections. Placebo injections matching the enoxaparin syringes.</description>
          </group>
          <group group_id="O2">
            <title>Dabigatran 150mg</title>
            <description>Patients were treated with 150mg dabigatran etexilate once daily as capsules for oral administration and placebo subcutaneous injections. Placebo injections matching the enoxaparin syringes.</description>
          </group>
          <group group_id="O3">
            <title>Enoxaparin</title>
            <description>Patients were treated with 40mg Enoxaparin once daily for subcutaneous injection and placebo capsules. Placebo capsules matching the dabigatran capsules.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Venous Thromboembolic Event and All-cause Mortality During Treatment Period</title>
          <description>Total Venous Thromboembolic Event (VTE) includes both proximal and distal deep vein thrombosis (DVT) (detected by routine bilateral venography), symptomatic DVT (confirmed by venous compression ultrasound, venography or autopsy) and pulmonary embolism (PE) (confirmed by pulmonary V-Q scintigraphy, chest x-ray, pulmonary angiography, spiral CT or autopsy).
All of these components and all deaths were centrally adjudicated by the VTE events committee, which was not aware of the treatment allocation of the patients.</description>
          <population>Full Analysis Set (all patients who had surgery and were randomised, received treatment, had an evaluable venogram for distal and proximal Deep Vein Thrombosis, or symptomatic Deep Vein Thrombosis, Pulmonary Embolism, or had died)</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="880"/>
                <count group_id="O2" value="874"/>
                <count group_id="O3" value="897"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="75"/>
                    <measurement group_id="O3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Risk difference versus Enoxaparin</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority Analysis with NI margin 7.7%. This results from the null-hypotheses of non-inferiority testing, where the rate difference has to be below 7.7%. Non-inferiority can only be shown with CI.</non_inferiority_desc>
            <p_value>0.5648</p_value>
            <p_value_desc>p-value is for superiority testing</p_value_desc>
            <method>Normal approximation</method>
            <method_desc>Normal approximation of independent binomial distribution without stratification</method_desc>
            <param_type>Risk Difference (Percentage)</param_type>
            <param_value>-0.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.9</ci_lower_limit>
            <ci_upper_limit>1.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Risk difference versus Enoxaparin</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority Analysis with NI margin 7.7%. This results from the null-hypotheses of non-inferiority testing, where the rate difference has to be below 7.7%. Non-inferiority can only be shown with CI.</non_inferiority_desc>
            <p_value>0.1339</p_value>
            <p_value_desc>p-value is for superiority testing</p_value_desc>
            <method>Normal approximation</method>
            <method_desc>Normal approximation of independent binomial distribution without stratification</method_desc>
            <param_type>Risk Difference (Percentage)</param_type>
            <param_value>1.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.6</ci_lower_limit>
            <ci_upper_limit>4.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Major Venous Thromboembolic Event and Venous Thromboembolic Event-related Mortality During Treatment Period</title>
        <description>Major Venous Thromboembolic Event (VTE) is defined as proximal DVT and PE, as adjudicated by the VTE events committee</description>
        <time_frame>First administration until 31-38 days</time_frame>
        <population>Full Analysis Set - major (all patients who had surgery and were randomised, received treatment, had an evaluable venogram for proximal Deep Vein Thrombosis, or had confirmed symptomatic Deep Vein Thrombosis, Pulmonary Embolism, or had died by a Venous Thromboembolic Event-related death)</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran 220mg</title>
            <description>Patients were treated with 220mg dabigatran etexilate once daily as capsules for oral administration and placebo subcutaneous injections. Placebo injections matching the enoxaparin syringes.</description>
          </group>
          <group group_id="O2">
            <title>Dabigatran 150mg</title>
            <description>Patients were treated with 150mg dabigatran etexilate once daily as capsules for oral administration and placebo subcutaneous injections. Placebo injections matching the enoxaparin syringes.</description>
          </group>
          <group group_id="O3">
            <title>Enoxaparin</title>
            <description>Patients were treated with 40mg Enoxaparin once daily for subcutaneous injection and placebo capsules. Placebo capsules matching the dabigatran capsules.</description>
          </group>
        </group_list>
        <measure>
          <title>Major Venous Thromboembolic Event and Venous Thromboembolic Event-related Mortality During Treatment Period</title>
          <description>Major Venous Thromboembolic Event (VTE) is defined as proximal DVT and PE, as adjudicated by the VTE events committee</description>
          <population>Full Analysis Set - major (all patients who had surgery and were randomised, received treatment, had an evaluable venogram for proximal Deep Vein Thrombosis, or had confirmed symptomatic Deep Vein Thrombosis, Pulmonary Embolism, or had died by a Venous Thromboembolic Event-related death)</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="909"/>
                <count group_id="O2" value="888"/>
                <count group_id="O3" value="917"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="38"/>
                    <measurement group_id="O3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Risk difference versus Enoxaparin</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3256</p_value>
            <method>Normal approximation</method>
            <method_desc>Normal approximation of independent binomial distribution without stratification</method_desc>
            <param_type>Risk Difference (Percentage)</param_type>
            <param_value>-0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.5</ci_lower_limit>
            <ci_upper_limit>0.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Risk difference versus Enoxaparin</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7052</p_value>
            <method>Normal approximation</method>
            <method_desc>Normal approximation of independent binomial distribution without stratification</method_desc>
            <param_type>Risk Difference (Percentage)</param_type>
            <param_value>0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.5</ci_lower_limit>
            <ci_upper_limit>2.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proximal Deep Vein Thrombosis During Treatment Period</title>
        <description>Proximal Deep Vein Thrombosis as adjudicated by the VTE events committee</description>
        <time_frame>First administration until 31-38 days</time_frame>
        <population>Full Analysis Set - pDVT (all patients who had surgery and were randomised, received treatment, had an evaluable venogram for proximal Deep Vein Thrombosis, or had confirmed symptomatic Deep Vein Thrombosis)</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran 220mg</title>
            <description>Patients were treated with 220mg dabigatran etexilate once daily as capsules for oral administration and placebo subcutaneous injections. Placebo injections matching the enoxaparin syringes.</description>
          </group>
          <group group_id="O2">
            <title>Dabigatran 150mg</title>
            <description>Patients were treated with 150mg dabigatran etexilate once daily as capsules for oral administration and placebo subcutaneous injections. Placebo injections matching the enoxaparin syringes.</description>
          </group>
          <group group_id="O3">
            <title>Enoxaparin</title>
            <description>Patients were treated with 40mg Enoxaparin once daily for subcutaneous injection and placebo capsules. Placebo capsules matching the dabigatran capsules.</description>
          </group>
        </group_list>
        <measure>
          <title>Proximal Deep Vein Thrombosis During Treatment Period</title>
          <description>Proximal Deep Vein Thrombosis as adjudicated by the VTE events committee</description>
          <population>Full Analysis Set - pDVT (all patients who had surgery and were randomised, received treatment, had an evaluable venogram for proximal Deep Vein Thrombosis, or had confirmed symptomatic Deep Vein Thrombosis)</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="905"/>
                <count group_id="O2" value="885"/>
                <count group_id="O3" value="914"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="35"/>
                    <measurement group_id="O3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Risk difference versus Enoxaparin</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1863</p_value>
            <method>Normal approximation</method>
            <method_desc>Normal approximation of independent binomial distribution without stratification</method_desc>
            <param_type>Risk Difference (Percentage)</param_type>
            <param_value>-1.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.7</ci_lower_limit>
            <ci_upper_limit>0.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Risk difference versus Enoxaparin</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7020</p_value>
            <method>Normal approximation</method>
            <method_desc>Normal approximation of independent binomial distribution without stratification</method_desc>
            <param_type>Risk Difference (Percentage)</param_type>
            <param_value>0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.4</ci_lower_limit>
            <ci_upper_limit>2.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Deep Vein Thrombosis During Treatment Period</title>
        <description>Total Deep Vein Thrombosis as adjudicated by the VTE events committee</description>
        <time_frame>First administration until 31-38 days</time_frame>
        <population>Full Analysis Set - tDVT (all patients who had surgery and were randomised, received treatment, had an evaluable venogram, or had confirmed symptomatic Deep Vein Thrombosis)</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran 220mg</title>
            <description>Patients were treated with 220mg dabigatran etexilate once daily as capsules for oral administration and placebo subcutaneous injections. Placebo injections matching the enoxaparin syringes.</description>
          </group>
          <group group_id="O2">
            <title>Dabigatran 150mg</title>
            <description>Patients were treated with 150mg dabigatran etexilate once daily as capsules for oral administration and placebo subcutaneous injections. Placebo injections matching the enoxaparin syringes.</description>
          </group>
          <group group_id="O3">
            <title>Enoxaparin</title>
            <description>Patients were treated with 40mg Enoxaparin once daily for subcutaneous injection and placebo capsules. Placebo capsules matching the dabigatran capsules.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Deep Vein Thrombosis During Treatment Period</title>
          <description>Total Deep Vein Thrombosis as adjudicated by the VTE events committee</description>
          <population>Full Analysis Set - tDVT (all patients who had surgery and were randomised, received treatment, had an evaluable venogram, or had confirmed symptomatic Deep Vein Thrombosis)</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="874"/>
                <count group_id="O2" value="871"/>
                <count group_id="O3" value="894"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="72"/>
                    <measurement group_id="O3" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Risk difference versus Enoxaparin</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3173</p_value>
            <method>Normal approximation</method>
            <method_desc>Normal approximation of independent binomial distribution without stratification</method_desc>
            <param_type>Risk Difference (Percentage)</param_type>
            <param_value>-1.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.3</ci_lower_limit>
            <ci_upper_limit>1.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Risk difference versus Enoxaparin</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1274</p_value>
            <method>Normal approximation</method>
            <method_desc>Normal approximation of independent binomial distribution without stratification</method_desc>
            <param_type>Risk Difference (Percentage)</param_type>
            <param_value>1.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.5</ci_lower_limit>
            <ci_upper_limit>4.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Symptomatic Deep Vein Thrombosis During Treatment Period</title>
        <description>Symptomatic Deep Vein Thrombosis, confirmed by venous compression ultrasound, venography or autopsy, and as adjudicated by the VTE events committee</description>
        <time_frame>First administration until 31-38 days</time_frame>
        <population>Full Analysis Set - op (all patients who are treated and operated)</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran 220mg</title>
            <description>Patients were treated with 220mg dabigatran etexilate once daily as capsules for oral administration and placebo subcutaneous injections. Placebo injections matching the enoxaparin syringes.</description>
          </group>
          <group group_id="O2">
            <title>Dabigatran 150mg</title>
            <description>Patients were treated with 150mg dabigatran etexilate once daily as capsules for oral administration and placebo subcutaneous injections. Placebo injections matching the enoxaparin syringes.</description>
          </group>
          <group group_id="O3">
            <title>Enoxaparin</title>
            <description>Patients were treated with 40mg Enoxaparin once daily for subcutaneous injection and placebo capsules. Placebo capsules matching the dabigatran capsules.</description>
          </group>
        </group_list>
        <measure>
          <title>Symptomatic Deep Vein Thrombosis During Treatment Period</title>
          <description>Symptomatic Deep Vein Thrombosis, confirmed by venous compression ultrasound, venography or autopsy, and as adjudicated by the VTE events committee</description>
          <population>Full Analysis Set - op (all patients who are treated and operated)</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1137"/>
                <count group_id="O2" value="1156"/>
                <count group_id="O3" value="1142"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison versus Enoxaparin</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0694</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison versus Enoxaparin</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0212</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pulmonary Embolism During Treatment Period</title>
        <description>Pulmonary embolism confirmed by pulmonary V-Q scintigraphy, chest x-ray, pulmonary angiography, spiral CT or autopsy, and as adjudicated by the VTE events committee</description>
        <time_frame>First administration until 31-38 days</time_frame>
        <population>Full Analysis Set - op (all patients who are treated and operated)</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran 220mg</title>
            <description>Patients were treated with 220mg dabigatran etexilate once daily as capsules for oral administration and placebo subcutaneous injections. Placebo injections matching the enoxaparin syringes.</description>
          </group>
          <group group_id="O2">
            <title>Dabigatran 150mg</title>
            <description>Patients were treated with 150mg dabigatran etexilate once daily as capsules for oral administration and placebo subcutaneous injections. Placebo injections matching the enoxaparin syringes.</description>
          </group>
          <group group_id="O3">
            <title>Enoxaparin</title>
            <description>Patients were treated with 40mg Enoxaparin once daily for subcutaneous injection and placebo capsules. Placebo capsules matching the dabigatran capsules.</description>
          </group>
        </group_list>
        <measure>
          <title>Pulmonary Embolism During Treatment Period</title>
          <description>Pulmonary embolism confirmed by pulmonary V-Q scintigraphy, chest x-ray, pulmonary angiography, spiral CT or autopsy, and as adjudicated by the VTE events committee</description>
          <population>Full Analysis Set - op (all patients who are treated and operated)</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1137"/>
                <count group_id="O2" value="1156"/>
                <count group_id="O3" value="1142"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison versus Enoxaparin</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5062</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison versus Enoxaparin</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3717</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Death During Treatment Period</title>
        <description>All cause death, as adjudicated by the VTE events committee</description>
        <time_frame>First administration until 31-38 days</time_frame>
        <population>Full Analysis Set - op (all patients who are treated and operated)</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran 220mg</title>
            <description>Patients were treated with 220mg dabigatran etexilate once daily as capsules for oral administration and placebo subcutaneous injections. Placebo injections matching the enoxaparin syringes.</description>
          </group>
          <group group_id="O2">
            <title>Dabigatran 150mg</title>
            <description>Patients were treated with 150mg dabigatran etexilate once daily as capsules for oral administration and placebo subcutaneous injections. Placebo injections matching the enoxaparin syringes.</description>
          </group>
          <group group_id="O3">
            <title>Enoxaparin</title>
            <description>Patients were treated with 40mg Enoxaparin once daily for subcutaneous injection and placebo capsules. Placebo capsules matching the dabigatran capsules.</description>
          </group>
        </group_list>
        <measure>
          <title>Death During Treatment Period</title>
          <description>All cause death, as adjudicated by the VTE events committee</description>
          <population>Full Analysis Set - op (all patients who are treated and operated)</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1137"/>
                <count group_id="O2" value="1156"/>
                <count group_id="O3" value="1142"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison versus Enoxaparin</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1240</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison versus Enoxaparin</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2497</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Venous Thromboembolic Event (VTE) and All-cause Mortality During the Follow-up Period</title>
        <description>Total Venous Thromboembolic Event (VTE) includes both proximal and distal deep vein thrombosis (DVT) (detected by routine bilateral venography), symptomatic DVT (confirmed by venous compression ultrasound, venography or autopsy) and pulmonary embolism (PE) (confirmed by pulmonary V-Q scintigraphy, chest x-ray, pulmonary angiography, spiral CT or autopsy).</description>
        <time_frame>end of treatment to day 91±7</time_frame>
        <population>Patients with any data available during follow-up</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran 220mg</title>
            <description>Patients were treated with 220mg dabigatran etexilate once daily as capsules for oral administration and placebo subcutaneous injections. Placebo injections matching the enoxaparin syringes.</description>
          </group>
          <group group_id="O2">
            <title>Dabigatran 150mg</title>
            <description>Patients were treated with 150mg dabigatran etexilate once daily as capsules for oral administration and placebo subcutaneous injections. Placebo injections matching the enoxaparin syringes.</description>
          </group>
          <group group_id="O3">
            <title>Enoxaparin</title>
            <description>Patients were treated with 40mg Enoxaparin once daily for subcutaneous injection and placebo capsules. Placebo capsules matching the dabigatran capsules.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Venous Thromboembolic Event (VTE) and All-cause Mortality During the Follow-up Period</title>
          <description>Total Venous Thromboembolic Event (VTE) includes both proximal and distal deep vein thrombosis (DVT) (detected by routine bilateral venography), symptomatic DVT (confirmed by venous compression ultrasound, venography or autopsy) and pulmonary embolism (PE) (confirmed by pulmonary V-Q scintigraphy, chest x-ray, pulmonary angiography, spiral CT or autopsy).</description>
          <population>Patients with any data available during follow-up</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1106"/>
                <count group_id="O2" value="1117"/>
                <count group_id="O3" value="1108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total VTE and all-cause mortality</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>asymptotic Deep Vein Thrombosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>symptotic Deep Vein Thrombosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pulmonary Embolism</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Bleeding Events (Defined According to Modified McMaster Criteria) During Treatment Period</title>
        <description>Major bleeding events were defined as
fatal
clinically overt associated with loss of haemoglobin &gt;=20g/L in excess of what was expected
clinically overt leading to the transfusion of &gt;=2 units packed cells or whole blood in excess of what was expected
symptomatic retroperitoneal, intracranial, intraocular or intraspinal
requiring treatment cessation
leading to re-operation
Clinically-relevant was defined as
spontaneous skin hematoma greater than or equal to 25 cm²
wound hematoma greater than or equal to 100 cm²
spontaneous nose bleed lasting longer than 5 min
macroscopic hematuria spontaneous or lasting longer than 24 hours if associated with an intervention
spontaneous rectal bleeding (more than a spot on toilet paper)
gingival bleeding lasting longer than 5 min
any other bleeding event considered clinically relevant by the investigator
Minor bleeding events were defined as all other bleeding events that did not fulfil the criteria from above.</description>
        <time_frame>First administration until 31-38 days</time_frame>
        <population>Treated set</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran 220mg</title>
            <description>Patients were treated with 220mg dabigatran etexilate once daily as capsules for oral administration and placebo subcutaneous injections. Placebo injections matching the enoxaparin syringes.</description>
          </group>
          <group group_id="O2">
            <title>Dabigatran 150mg</title>
            <description>Patients were treated with 150mg dabigatran etexilate once daily as capsules for oral administration and placebo subcutaneous injections. Placebo injections matching the enoxaparin syringes.</description>
          </group>
          <group group_id="O3">
            <title>Enoxaparin</title>
            <description>Patients were treated with 40mg Enoxaparin once daily for subcutaneous injection and placebo capsules. Placebo capsules matching the dabigatran capsules.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Bleeding Events (Defined According to Modified McMaster Criteria) During Treatment Period</title>
          <description>Major bleeding events were defined as
fatal
clinically overt associated with loss of haemoglobin &gt;=20g/L in excess of what was expected
clinically overt leading to the transfusion of &gt;=2 units packed cells or whole blood in excess of what was expected
symptomatic retroperitoneal, intracranial, intraocular or intraspinal
requiring treatment cessation
leading to re-operation
Clinically-relevant was defined as
spontaneous skin hematoma greater than or equal to 25 cm²
wound hematoma greater than or equal to 100 cm²
spontaneous nose bleed lasting longer than 5 min
macroscopic hematuria spontaneous or lasting longer than 24 hours if associated with an intervention
spontaneous rectal bleeding (more than a spot on toilet paper)
gingival bleeding lasting longer than 5 min
any other bleeding event considered clinically relevant by the investigator
Minor bleeding events were defined as all other bleeding events that did not fulfil the criteria from above.</description>
          <population>Treated set</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1146"/>
                <count group_id="O2" value="1163"/>
                <count group_id="O3" value="1154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Major</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clinical relevant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="55"/>
                    <measurement group_id="O3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Minor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                    <measurement group_id="O2" value="72"/>
                    <measurement group_id="O3" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1005"/>
                    <measurement group_id="O2" value="1021"/>
                    <measurement group_id="O3" value="1022"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison versus Enoxaparin</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4352</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison versus Enoxaparin</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6037</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Blood Transfusion</title>
        <description>Blood transfusion for treated and operated patients on Day of surgery.</description>
        <time_frame>Day 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran 220mg</title>
            <description>Patients were treated with 220mg dabigatran etexilate once daily as capsules for oral administration and placebo subcutaneous injections. Placebo injections matching the enoxaparin syringes.</description>
          </group>
          <group group_id="O2">
            <title>Dabigatran 150mg</title>
            <description>Patients were treated with 150mg dabigatran etexilate once daily as capsules for oral administration and placebo subcutaneous injections. Placebo injections matching the enoxaparin syringes.</description>
          </group>
          <group group_id="O3">
            <title>Enoxaparin</title>
            <description>Patients were treated with 40mg Enoxaparin once daily for subcutaneous injection and placebo capsules. Placebo capsules matching the dabigatran capsules.</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Transfusion</title>
          <description>Blood transfusion for treated and operated patients on Day of surgery.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1137"/>
                <count group_id="O2" value="1156"/>
                <count group_id="O3" value="1142"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Patients with &gt;=1 transfusions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="517"/>
                    <measurement group_id="O2" value="531"/>
                    <measurement group_id="O3" value="542"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients with &gt;=1 non-autologous transfusions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="259"/>
                    <measurement group_id="O2" value="266"/>
                    <measurement group_id="O3" value="286"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Volume of Blood Loss</title>
        <description>Volume of blood loss for treated and operated patients during surgery.</description>
        <time_frame>Day 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran 220mg</title>
            <description>Patients were treated with 220mg dabigatran etexilate once daily as capsules for oral administration and placebo subcutaneous injections. Placebo injections matching the enoxaparin syringes.</description>
          </group>
          <group group_id="O2">
            <title>Dabigatran 150mg</title>
            <description>Patients were treated with 150mg dabigatran etexilate once daily as capsules for oral administration and placebo subcutaneous injections. Placebo injections matching the enoxaparin syringes.</description>
          </group>
          <group group_id="O3">
            <title>Enoxaparin</title>
            <description>Patients were treated with 40mg Enoxaparin once daily for subcutaneous injection and placebo capsules. Placebo capsules matching the dabigatran capsules.</description>
          </group>
        </group_list>
        <measure>
          <title>Volume of Blood Loss</title>
          <description>Volume of blood loss for treated and operated patients during surgery.</description>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1127"/>
                <count group_id="O2" value="1147"/>
                <count group_id="O3" value="1133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="457" spread="304"/>
                    <measurement group_id="O2" value="435" spread="271"/>
                    <measurement group_id="O3" value="463" spread="291"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Laboratory Analyses</title>
        <description>Frequency of patients with possible clinically significant abnormalities.</description>
        <time_frame>First administration to end of study</time_frame>
        <population>Treated patients</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran 220mg</title>
            <description>Patients were treated with 220mg dabigatran etexilate once daily as capsules for oral administration and placebo subcutaneous injections. Placebo injections matching the enoxaparin syringes.</description>
          </group>
          <group group_id="O2">
            <title>Dabigatran 150mg</title>
            <description>Patients were treated with 150mg dabigatran etexilate once daily as capsules for oral administration and placebo subcutaneous injections. Placebo injections matching the enoxaparin syringes.</description>
          </group>
          <group group_id="O3">
            <title>Enoxaparin</title>
            <description>Patients were treated with 40mg Enoxaparin once daily for subcutaneous injection and placebo capsules. Placebo capsules matching the dabigatran capsules.</description>
          </group>
        </group_list>
        <measure>
          <title>Laboratory Analyses</title>
          <description>Frequency of patients with possible clinically significant abnormalities.</description>
          <population>Treated patients</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1103"/>
                <count group_id="O2" value="1098"/>
                <count group_id="O3" value="1103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AST increase N=(1103;1097;1103)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST decrease N=(1103;1097;1103)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT increase N=(1103;1098;1103)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT decrease N=(1103;1098;1103)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin increase N=(1102;1094;1102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin decrease N=(1102;1094;1102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>13 weeks</time_frame>
      <desc>Treatment emergent events (last medication + 3 days)</desc>
      <group_list>
        <group group_id="E1">
          <title>Dabigatran 220mg</title>
          <description>Patients were treated with 220mg dabigatran etexilate once daily as capsules for oral administration and placebo subcutaneous injections. Placebo injections matching the enoxaparin syringes.</description>
        </group>
        <group group_id="E2">
          <title>Dabigatran 150mg</title>
          <description>Patients were treated with 150mg dabigatran etexilate once daily as capsules for oral administration and placebo subcutaneous injections. Placebo injections matching the enoxaparin syringes.</description>
        </group>
        <group group_id="E3">
          <title>Enoxaparin</title>
          <description>Patients were treated with 40mg Enoxaparin once daily for subcutaneous injection and placebo capsules. Placebo capsules matching the dabigatran capsules.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (9.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="89" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="91" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="82" subjects_at_risk="1154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1154"/>
              </event>
              <event>
                <sub_title>Acute right ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1154"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1154"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1154"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1154"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1154"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1154"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1154"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1154"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1154"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="1154"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Angle closure glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1154"/>
              </event>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1154"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1154"/>
              </event>
              <event>
                <sub_title>Diarrhoea haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1154"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1154"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1154"/>
              </event>
              <event>
                <sub_title>Gastritis haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1154"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1154"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1154"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1154"/>
              </event>
              <event>
                <sub_title>Ileus paralytic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1154"/>
              </event>
              <event>
                <sub_title>Intestinal ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1154"/>
              </event>
              <event>
                <sub_title>Intra-abdominal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1154"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1154"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1154"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1154"/>
              </event>
              <event>
                <sub_title>Small intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1154"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1154"/>
              </event>
              <event>
                <sub_title>Drug ineffective</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1154"/>
              </event>
              <event>
                <sub_title>Feeling hot and cold</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1154"/>
              </event>
              <event>
                <sub_title>Impaired healing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1154"/>
              </event>
              <event>
                <sub_title>Inflammation of wound</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1154"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1154"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1154"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1154"/>
              </event>
              <event>
                <sub_title>Systemic inflammatory response syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1154"/>
              </event>
              <event>
                <sub_title>Wound necrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1154"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1154"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1154"/>
              </event>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1154"/>
              </event>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1154"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Arthritis infective</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1154"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1154"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1154"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1154"/>
              </event>
              <event>
                <sub_title>Oesophageal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1154"/>
              </event>
              <event>
                <sub_title>Perineal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1154"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1154"/>
              </event>
              <event>
                <sub_title>Postoperative infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1154"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1154"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1154"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1154"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1154"/>
              </event>
              <event>
                <sub_title>Wound abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1154"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="1154"/>
              </event>
              <event>
                <sub_title>Wound infection staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arterial injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1154"/>
              </event>
              <event>
                <sub_title>Bone fissure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1154"/>
              </event>
              <event>
                <sub_title>Contrast media reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1154"/>
              </event>
              <event>
                <sub_title>Device breakage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1154"/>
              </event>
              <event>
                <sub_title>Dislocation of joint prosthesis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="1154"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1154"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1154"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1154"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1154"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1154"/>
              </event>
              <event>
                <sub_title>Joint dislocation postoperative</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1154"/>
              </event>
              <event>
                <sub_title>Meniscus lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1154"/>
              </event>
              <event>
                <sub_title>Operative haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1154"/>
              </event>
              <event>
                <sub_title>Post procedural discharge</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1154"/>
              </event>
              <event>
                <sub_title>Post procedural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1154"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1154"/>
              </event>
              <event>
                <sub_title>Postoperative thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1154"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1154"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1154"/>
              </event>
              <event>
                <sub_title>Seroma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1154"/>
              </event>
              <event>
                <sub_title>Stress fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1154"/>
              </event>
              <event>
                <sub_title>Traumatic haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1154"/>
              </event>
              <event>
                <sub_title>Wound complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1154"/>
              </event>
              <event>
                <sub_title>Wound secretion</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1154"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1154"/>
              </event>
              <event>
                <sub_title>Oxygen saturation decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1154"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1154"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1154"/>
              </event>
              <event>
                <sub_title>Haemarthrosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1154"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1154"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1154"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Langerhans' cell granulomatosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1154"/>
              </event>
              <event>
                <sub_title>Ovarian cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1154"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1154"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1154"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1154"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1154"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Neurogenic bladder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1154"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1154"/>
              </event>
              <event>
                <sub_title>Urethral stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1154"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Prostatism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1154"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1154"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1154"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1154"/>
              </event>
              <event>
                <sub_title>Pulmonary infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1154"/>
              </event>
              <event>
                <sub_title>Respiratory depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Decubitus ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1154"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Immobile</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1154"/>
              </event>
              <event>
                <sub_title>Immobilisation prolonged</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Air embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1154"/>
              </event>
              <event>
                <sub_title>Arterial rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1154"/>
              </event>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1154"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="1154"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1154"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1154"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1154"/>
              </event>
              <event>
                <sub_title>Peripheral embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1154"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1154"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1154"/>
              </event>
              <event>
                <sub_title>Venous thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1154"/>
              </event>
              <event>
                <sub_title>Wound haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1154"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (9.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="620" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="642" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="648" subjects_at_risk="1154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="146" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="140" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="149" subjects_at_risk="1154"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="238" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="258" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="289" subjects_at_risk="1154"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="193" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="185" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="191" subjects_at_risk="1154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="79" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="56" subjects_at_risk="1154"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="121" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="140" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="162" subjects_at_risk="1154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Wound secretion</sub_title>
                <counts group_id="E1" subjects_affected="94" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="88" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="60" subjects_at_risk="1154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="77" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="88" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="80" subjects_at_risk="1154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="81" subjects_at_risk="1146"/>
                <counts group_id="E2" subjects_affected="76" subjects_at_risk="1163"/>
                <counts group_id="E3" subjects_affected="81" subjects_at_risk="1154"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

